Consolidated Statements of Cash Flows - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities:
Net income (loss)		$ (19)	$ 349
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Interest credited to policyholders’ account balances		435	288
Policy charges and fee income		(524)	(591)
Net derivative (gains) losses		841	(144)
Credit and intent to sell losses on available for sale debt securities and loans		64	(10)
Investment (gains) losses, net		14	332
Realized and unrealized (gains) losses on trading securities		(12)	16
Non-cash long-term incentive compensation expense		9	13
Amortization and depreciation		136	88
Equity (income) loss from limited partnerships		(15)	(93)
Remeasurement of liability for future policy benefits		13	(401)
Change in Market Risk Benefits		24	14
Changes in:
Reinsurance recoverable	[1]	(370)	(353)
Capitalization of deferred policy acquisition costs		(124)	(182)
Future policy benefits		(115)	67
Current and deferred income taxes	[1]	(700)	64
Other, net		55	(270)
Net cash provided by (used in) operating activities		(288)	(813)
Proceeds from the sale/maturity/prepayment of:
Fixed maturities, available-for-sale		1,270	8,478
Mortgage loans on real estate		81	280
Trading account securities		55	36
Short-term investments		179	0
Other		188	89
Payment for the purchase/origination of:
Fixed maturities, available-for-sale		(821)	(8,109)
Mortgage loans on real estate		(580)	(688)
Trading account securities		(59)	(55)
Other		(232)	(181)
Cash settlements related to derivative instruments, net		(103)	302
Investment in capitalized software, leasehold improvements and EDP equipment		(5)	7
Other, net		44	56
Net cash provided by (used in) investing activities		17	215
Cash flows from financing activities:
Deposits		3,167	3,041
Withdrawals		(2,643)	(2,232)
Transfers (to) from Separate Accounts		315	500
Payments of MRB benefits		(172)	(122)
Change in collateralized pledged assets		(7)	(39)
Change in collateralized pledged liabilities		569	548
Purchase (redemption) of noncontrolling interests of consolidated company-sponsored investment funds		1	2
Other, net		0	(25)
Net cash provided by (used in) financing activities		1,230	1,673
Change in cash and cash equivalents		959	1,075
Cash and cash equivalents, beginning of year		797	1,815
Cash and cash equivalents, end of year		$ 1,756	$ 2,890

[1] For the period ended March 31, 2023 includes a release of $586 million deferred tax valuation allowance. Refer to Note 11 of these Consolidated Financial Statements.